KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma

NCT ID: NCT02471911

Last Updated: 2022-04-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 22 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-12-11
• Study Completion Date: 2021-10-14

Brief Summary

This study evaluates the addition of selinexor (KPT-330) to RICE chemotherapy in the treatment of relapsed and refractory aggressive B-Cell Lymphoma, with the goal of improved response rates (as compared to RICE chemotherapy alone).

Detailed Description

Although aggressive B-cell lymphomas are potentially curable with front-line chemotherapy, at least one-third of patients experience progression or relapse. Second-line regimens such as rituximab, ifosfamide, carboplatin, and etoposide (RICE) are administered with the goal of cytoreduction prior to autologous stem cell transplantation (ASCT) in eligible patients. However, half of patients who receive salvage treatment and ASCT are still not cured.

Selinexor is a Selective Inhibitor of Nuclear Export / SINE compound, which is a new class of molecule. SINE compounds have been shown to induce apoptotic cell death in pre-clinical models of AML, CLL, T-ALL, and Ph+ ALL as well as B and T-cell non-Hodgkin lymphomas. Preliminarily, selinexor has demonstrated promising single-agent clinical activity in patients with previously treated NHL including DLBCL, warranting further investigation. Based on promising preclinical and clinical data, selinexor is currently under evaluation in combination with chemotherapy for solid tumors.

The investigators hypothesize that the combination of selinexor plus RICE will be well-tolerated and clinically active in participants with previously treated aggressive B-cell lymphomas and propose a phase I trial to evaluate this combination. Moreover, Investigators will evaluate primary patient samples before and after selinexor to investigate the mechanisms of action of selinexor, including the mechanisms by which selinexor sensitizes cells to chemotherapy, and evaluate other novel drug combinations in aggressive B-cell lymphomas.

Conditions

Diffuse Large B-Cell Lymphoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

All subjects

All subjects will receive KPT-330 (selinexor) on days -5 and -3 starting one week before RICE chemotherapy is started. Once chemotherapy starts, selinexor will be given on days 1, 3, and 5 of each chemotherapy cycle.

RICE chemotherapy will consist of Rituximab, ifosfamide, carboplatin, etoposide, and dexamethasone.

Group Type: EXPERIMENTAL

KPT-330

Intervention Type: DRUG

KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.

Rituximab

Intervention Type: DRUG

IV Rituximab 375 mg/m2 on D1

Etoposide

Intervention Type: DRUG

IV Etoposide 100 mg/m2 on D1-3

Carboplatin

Intervention Type: DRUG

IV Carboplatin AUC 5 on D2

Ifosfamide

Intervention Type: DRUG

IV Ifosfamide 5 g/m2 on D2

Dexamethasone

Intervention Type: DRUG

20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5

Interventions

KPT-330

KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.

Intervention Type: DRUG

Rituximab

IV Rituximab 375 mg/m2 on D1

Intervention Type: DRUG

Etoposide

IV Etoposide 100 mg/m2 on D1-3

Intervention Type: DRUG

Carboplatin

IV Carboplatin AUC 5 on D2

Intervention Type: DRUG

Ifosfamide

IV Ifosfamide 5 g/m2 on D2

Intervention Type: DRUG

Dexamethasone

20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5

Intervention Type: DRUG

Other Intervention Names

Selinexor; Rituxan

Eligibility Criteria

Inclusion Criteria

• Patients must have histologically confirmed aggressive B-cell non-Hodgkin lymphomas:

• DLBCL including ABC, GCB or PMBCL subtypes
• Double/triple hit lymphomas
• Indolent lymphomas transformed to aggressive lymphomas
• Follicular lymphomas grade 3B
• Patients must have received at least two cycles of anthracycline based chemotherapy administered with curative intent and one of the following:

• failed to have achieve at least a partial response after 2 or more cycles
• failed to achieve a complete response after 6 or more cycles
• progressed after an initial response
• Patients must be age ≥18 years.
• Patients must have at least one site of measurable disease, 1.5 cm in diameter or greater.
• Patients must have ECOG performance status of 0-2.
• Patients must have laboratory test results within these ranges:

• Absolute neutrophil count ≥ 1500/mm³
• Platelet count ≥ 100,000/mm³
• Serum creatinine clearance ≥40 mL/min
• Total bilirubin ≤ 1.5x ULN. Higher levels are acceptable if these can be attributed to active hemolysis or ineffective erythropoiesis.
• AST (SGOT) and ALT (SGPT) ≤ 2x ULN
• Women of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test prior to selinexor treatment. Male patients must use an effective barrier method of contraception if sexually active with a female of child-bearing potential.

• Acceptable methods of contraception are condoms with contraceptive foam, oral, implantable or injectable contraceptives, contraceptive patch, intrauterine device, diaphragm with spermicidal gel, or a sexual partner who is surgically sterilized or post-menopausal.
• For both male and female patients, effective methods of contraception must be used throughout the study and for three months following the last dose.
• Patients must be able to understand and willing to sign a written informed consent document.
• Patients must be able to adhere to the study visit schedule and other protocol requirements.
• Patients must not have any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
• Patients must not have any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

Exclusion Criteria

• Patients with hyperuricemia or other potential signs of tumor lysis syndrome
• Patients with more than minimally symptomatic disease (i.e. > grade 1), high tumor burden, or other indication for urgent treatment.
• Patients who have had prior malignancies (other than B-cell lymphomas) for ≤5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast.
• Patients who have had other anti-cancer therapy, including radiation or experimental drug or therapy, within 28 days of enrollment.
• Patients with known HIV, active hepatitis B, active hepatitis C.
• Patients with known central nervous system involvement by lymphoma.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Karyopharm Therapeutics Inc

INDUSTRY

Sponsor Role: collaborator

The Leukemia and Lymphoma Society

OTHER

Sponsor Role: collaborator

FDA Office of Orphan Products Development

FED

Sponsor Role: collaborator

Weill Medical College of Cornell University

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Peter Martin, MD

Role: PRINCIPAL_INVESTIGATOR

Weill Medical College of Cornell University

Locations

Weill Cornell Medical College

New York, New York, United States

Countries

United States

Other Identifiers

1502015891

Identifier Type: -

Identifier Source: org_study_id